A meta-analysis and real-world cohort study on the sex-related differences in efficacy and safety of immunotherapy for hepatocellular carcinoma

Resource type: Publication Publication
  • Authors
    Balcar L.; Scheiner B.; Fulgenzi C.A.M.; D'Alessio A.; Pomej K.; Roig M.B.; Meyer E.L.; Che J.; Nishida N.; Lee P.-C.; Wu L.; Ang C.; Krall A.; Saeed A.; Stefanini B.; Cammarota A.; Pressiani T.; Abugabal Y.I.; Chamseddine S.; Wietharn B.; Parisi A.; Huang Y.-H.; Phen S.; Vivaldi C.; Salani F.; Masi G.; Bettinger D.; Vogel A.; von Felden J.; Schulze K.; Silletta M.; Trauner M.; Samson A.; Wege H.; Piscaglia F.; Galle P.R.; Stauber R.; Kudo M.; Singal A.G.; Itani A.; Ulahannan S.V.; Parikh N.D.; Cortellini A.; Kaseb A.; Rimassa L.; Chon H.J.; Pinato D.J.; Pinter M.
  • Type
    Original research
  • Journal
    JHEP Reports
  • Publication Date
    2024
  • Abstract

    Background & Aims: Sex-related differences in the immune pathogenesis of hepatocellular carcinoma (HCC), particularly related to oestrogen-dependent secretion of pro-tumourigenic cytokines, are well-known. Whether sex influences the efficacy and safety of immunotherapy is not known.

Access Publication